Chantix (varenicline): Label Change – Risk of Certain Cardiovascular Adverse Events

Audience: Family Medicine, Cardiology [UPDATED 07/22/2011] FDA has approved an updated drug label for Chantix (varenicline) to include information about the efficacy and safety of the drug in two patient populations who may benefit greatly from…

Related posts:

1. Chantix (varenicline): Label Change – Risk of Certain Cardiovascular Adverse Events Audience: Family Medicine, Cardiology [Posted 06/16/2011] ISSUE: FDA notified healthcare...
2. Avandia (rosiglitazone): REMS – Risk of Cardiovascular Events Audience: Endocrinology, Cardiology includes Avandia, Avandamet, and Avandaryl [UPDATED 05/18/2011]...